Schulhoff & Co. Inc. Raises Stock Position in Pyxis Oncology, Inc. $PYXS

Schulhoff & Co. Inc. raised its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 125.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 275,000 shares of the company’s stock after purchasing an additional 153,000 shares during the quarter. Schulhoff & Co. Inc. owned approximately 0.44% of Pyxis Oncology worth $302,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. 683 Capital Management LLC increased its position in Pyxis Oncology by 32.5% during the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after purchasing an additional 135,000 shares during the period. Pier 88 Investment Partners LLC increased its position in Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after purchasing an additional 292,370 shares during the period. Nuveen LLC purchased a new position in Pyxis Oncology during the 1st quarter valued at $125,000. Acadian Asset Management LLC purchased a new position in Pyxis Oncology during the 1st quarter valued at $81,000. Finally, Bank of America Corp DE increased its position in Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the period. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $3.58 on Wednesday. The stock has a market cap of $222.03 million, a price-to-earnings ratio of -2.24 and a beta of 1.33. The firm’s 50-day moving average is $2.12 and its 200 day moving average is $1.48. Pyxis Oncology, Inc. has a 1 year low of $0.83 and a 1 year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter. On average, equities analysts expect that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on PYXS. Guggenheim started coverage on shares of Pyxis Oncology in a research report on Wednesday, September 3rd. They set a “buy” rating and a $5.00 price objective on the stock. Zacks Research upgraded shares of Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Tuesday, August 19th. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Friday, October 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.